Revvity, Inc.
NYSE:RVTYMedical - Diagnostics & Research
-$3.40 today
- Market cap
- $17.02B
- Beta
- 1.11
- P/E (TTM)
- 45.4
- EPS (TTM)
- $2.15
- Dividend yield
- 0.29%
Volume 1.09M
Average 1.27M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Revvity, Inc.
NYSE:RVTY
Intrinsic Alpha fair value
Locked
Current Price
$152.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -22.7% | +30.2% (5yr)2 analysts |
| Revenue | N/A | N/A | -4.8% | +4.6% (5yr)11 analysts |
| Net Income | N/A | N/A | -24.8% | +29.6% (5yr)11 analysts |
| EBIT | N/A | N/A | -23.0% | +30.7% (5yr)11 analysts |
Analysis
Recent growth has been strongest in Revenue at -4.8% over three years. Forward estimates point to EBIT at +30.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Thermo Fisher Scientific Inc. NYSE:TMO | $259.44B | $700.22 | Fairly Valued | 25.3 | +20.59% |
Danaher Corporation NYSE:DHR | $163.94B | $233.02 | Overvalued | 34.0 | +1.64% |
Agilent Technologies, Inc. NYSE:A | $49.05B | $173.96 | Overvalued | 25.5 | +23.77% |
Waters Corporation NYSE:WAT | $45.24B | $460.25 | Overvalued | 65.2 | +23.76% |
Mettler-Toledo International Inc. NYSE:MTD | $34.59B | $1,738.91 | Overvalued | 26.6 | +24.41% |
Charles River Laboratories International, Inc. NYSE:CRL | $16.19B | $337.97 | Overvalued | -48.3 | +105.04% |
Bio-Techne Corporation NASDAQ:TECH | $11.44B | $72.80 | Overvalued | 78.3 | +25.52% |
Qiagen N.V. NYSE:QGEN | $10.30B | $49.89 | Undervalued | 18.6 | +17.44% |
Bio-Rad Laboratories, Inc. NYSE:BIO | $9.85B | $366.36 | Fairly Valued | 45.4 | +20.27% |
Mesa Laboratories, Inc. NASDAQ:MLAB | $781.31M | $139.01 | Undervalued | 78.3 | +96.20% |
Continue the stock analysis
Jump to another research area for this company.